APA

Weiss G. J., Jameson G., Von Hoff D. D., Valsasina B., Davite C., Di Giulio C., Fiorentini F., Alzani R., Carpinelli P., Di Sanzo A., Galvani A., Isacchi A. & Ramanathan R. K. (20181227). Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. : Investigational new drugs.

Chicago

Weiss Glen J, Jameson Gayle, Von Hoff Daniel D, Valsasina Barbara, Davite Cristina, Di Giulio Claudia, Fiorentini Francesco, Alzani Rachele, Carpinelli Patrizia, Di Sanzo Alessandro, Galvani Arturo, Isacchi Antonella and Ramanathan Ramesh K. 20181227. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. : Investigational new drugs.

Harvard

Weiss G. J., Jameson G., Von Hoff D. D., Valsasina B., Davite C., Di Giulio C., Fiorentini F., Alzani R., Carpinelli P., Di Sanzo A., Galvani A., Isacchi A. and Ramanathan R. K. (20181227). Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. : Investigational new drugs.

MLA

Weiss Glen J, Jameson Gayle, Von Hoff Daniel D, Valsasina Barbara, Davite Cristina, Di Giulio Claudia, Fiorentini Francesco, Alzani Rachele, Carpinelli Patrizia, Di Sanzo Alessandro, Galvani Arturo, Isacchi Antonella and Ramanathan Ramesh K. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. : Investigational new drugs. 20181227.